[
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: Growth Portfolio Surpasses Legacy, Driving Oncology And Immunology Leadership",
    "summary": "Bristol-Myers Squibb is a Strong Buy at current levels, with a $54 price target and attractive 5.2% dividend yield.",
    "url": "https://finnhub.io/api/news?id=948f1cedf73e85a5f01c7c088ee312f01ca33a0690ec786d7654c5c8d3bee7ab",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757238471,
      "headline": "Bristol-Myers Squibb: Growth Portfolio Surpasses Legacy, Driving Oncology And Immunology Leadership",
      "id": 136662246,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192786673/image_2192786673.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb is a Strong Buy at current levels, with a $54 price target and attractive 5.2% dividend yield.",
      "url": "https://finnhub.io/api/news?id=948f1cedf73e85a5f01c7c088ee312f01ca33a0690ec786d7654c5c8d3bee7ab"
    }
  }
]